NCT01844973已完成1 期
Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Peak Plasma concentration (Cmax) of M5181
研究概览
简要总结
This study is to evaluate the pharmacokinetics and safety of M518101 in male and female plaque psoriasis patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Who are able and willing to give signed informed consent
- •Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator.
- •Who have ≥20% of body surface area (BSA) afflicted with plaques
- •Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study.
排除标准
- •Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity.
- •BMI > 32.0 kg/m2
- •Who are pregnant or lactating.
- •Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease.
- •Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
- •Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study.
- •Whose serum calcium levels exceed the upper limit of reference range
- •Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of randomization.
- •Who have taken any durg with known effects on calcium metabolism within 30days of randomization
- •Who have been treated with any drug with a known risk of QT prolongation within 30days of randomization.
研究组 & 干预措施
Vehicle
Placebo Comparator
干预措施: Vehicle (Drug)
M518101
Active Comparator
干预措施: M518101 (Drug)
结局指标
主要结局
Peak Plasma concentration (Cmax) of M5181
时间窗: 0, 1, 2, 4, 6, 9 12h after dosing
Area under the plasma concentration versus time curve (AUC) of M5181
时间窗: 0, 1, 2, 4, 6, 9 12h after dosing
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis PatientsPlaque PsoriasisNCT01301157Maruho Co., Ltd.294
终止
1 期
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCCSquamous Cell Carcinoma of the Head and NeckNCT04659369Taizhou Mabtech Pharmaceutical Co.,Ltd21
已完成
1 期
Multiple Ascending Dose Study of CTP-692 in Healthy VolunteersHealthyNCT03880253Concert Pharmaceuticals30
Unknown
不适用
A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim TherapyPneumocystis Jirovecii PneumoniaNCT02045160National Taiwan University Hospital1,000
已完成
1 期
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye DropsHealthy VolunteersNCT01434888Santen Oy15